

Resource Summary Report

Generated by [dkNET](#) on Sep 19, 2026

SUM190PT

RRID:CVCL_3423

Type: Cell Line

Proper Citation

RRID:CVCL_3423

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3423

Proper Citation: RRID:CVCL_3423

Description: Cell line SUM190PT is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast inflammatory carcinoma

Defining Citation: [PMID:10424408](#), [PMID:10604729](#), [PMID:10969801](#), [PMID:15677628](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:23151021](#), [PMID:23401782](#), [PMID:23601657](#), [PMID:23784380](#), [PMID:24162158](#), [PMID:25877200](#), [PMID:28196595](#), [PMID:32715085](#), [PMID:35042871](#)

Comments: Characteristics: ER-negative, PR-negative and ERBB2-positive., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SUM190PT

Synonyms: SUM-190PT, SUM 190PT, SUM-190, SUM 190, SUM190, 190PT

Cross References: BTO:BTO_0005477, EFO:EFO_0001243, ArrayExpress:E-MTAB-11134, ArrayExpress:E-TABM-157, BioSample:SAMN03471033, cancercellines:CVCL_3423, Cosmic:904391, Cosmic:1046941, Cosmic:1287899, Cosmic:1289414, Cosmic:1460244, Cosmic:1603225, DepMap:ACH-001393, GEO:GSM217602, GEO:GSM350534, GEO:GSM847436, GEO:GSM847503, GEO:GSM1008918, GEO:GSM1053734, GEO:GSM1215269, GEO:GSM1238141,

IARC_TP53:24367, LINCS_HMS:51121, PharmacDB:SUM190_1511_2019, Progenetix:CVCL_3423, SLKBase:263, Wikidata:Q54970845

ID: CVCL_3423

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260913T010144+0000

Ratings and Alerts

No rating or validation information has been found for SUM190PT.

No alerts have been found for SUM190PT.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. *Cancer research*, 86(6), 1467.

Rampa DR, et al. (2026) Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1454.

Mughees M, et al. (2025) Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers. *Molecular cancer therapeutics*, 24(9), 1453.

Watson SS, et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. *Cell systems*, 6(3), 329.